RxDoctor Payments DataLook up a doctor →

John Volpi, MD

Vascular Neurology · Houston, TXNPI 1346443843

Payments from drug & device makers

$684,023in general payments, 2019–2025

Across 818 payments — averaging $836.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$193K
  • Novartis$144K
  • Medtronic$106K
  • Amgen$84K
  • W. L. Gore & Associates, Inc.$81K
  • Daiichi Sankyo Inc.$29K
  • plus $46K from 35 others

What the payments were for

  • Consulting fees$61,99015%
  • Speaking & faculty fees$299,36074%
  • Travel & lodging$31,5848%
  • Food & beverage$13,7073%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684,023 in reported general payments places this provider in the 95th percentile of 76 vascular neurology providers in Texas.

See all vascular neurology providers in Texas

Medicare billing

Part B allowed, 2024
$295,126
Medicare patients
792
Services billed
1,971

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban424$481,741
EliquisApixaban193$202,178
Repatha SureclickEvolocumab124$150,524
NuedextaDextromethorphan Hbr/Quinidine58$112,489
Praluent PenAlirocumab20$15,711
Repatha PushtronexEvolocumab17$15,656
BrilintaTicagrelor22$13,325
Ezetimibe182$4,888
Lacosamide22$4,346
Ramelteon27$3,969
ClopidogrelClopidogrel Bisulfate242$3,530
Rosuvastatin Calcium236$3,295
Memantine Hcl83$2,377
Enoxaparin Sodium11$2,129
Atorvastatin Calcium217$2,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$193,465$481,741424 claims
PfizerEliquis$303$202,178193 claims
Avanir Pharmaceuticals, Inc.Nuedexta$163$112,48958 claims
AstraZenecaBrilinta$726$13,32522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 vascular neurology providers in Texas.

Other vascular neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →